Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28970797 | 0.86 | CNR2 (0.56) | CNR2CNR1EPHX1TSHRDGKA | |
| SCHEMBL5948434 | 0.86 | ALDH1A1 (0.46) | CNR2CNR1CA12CA14CA2 | |
| SCHEMBL27761052 | 0.85 | CNR2 (0.58) | CNR2CNR1CA12CA14CA2 | |
| SCHEMBL3416078 | 0.85 | CNR2 (0.63) | CNR2CNR1CA12CA14CA2 | |
| SCHEMBL11839026 | 0.85 | CNR2 (0.54) | CNR2CNR1CA12CA14CA2 | |
| SCHEMBL22556292 | 0.85 | CNR2 (0.58) | CNR2CNR1CA12CA14CA2 | |
| SCHEMBL24728584 | 0.83 | CNR2 (0.57) | CNR2CNR1CA12CA14CA2 | |
| SCHEMBL4837108 | 0.83 | CNR2 (0.66) | CNR2CNR1EPHX1CASP2DGKA | |
| SCHEMBL19060157 | 0.83 | CNR2 (0.57) | CNR2CNR1CA12CA14CA2 | |
| SCHEMBL20548310 | 0.83 | CNR2 (0.66) | CNR2CNR1EPHX1CASP2DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912165-B2 | Methods of skin treatment and use of water-soluble β-(1,3) glucans as active agents for producing therapeutic skin treatment agents | BIOTEC PHARMACON ASA (NO) | 2014-12-16 | — | — | US | disclosed |
| US-20130296265-A1 | Methods of Skin Treatment and Use of Water-Soluble Beta-(1,3) Glucans as Active Agents for Producing Therapeutic Skin Treatment Agents | BIOTEC PHARMACON ASA (NO) | 2013-11-07 | — | — | US | disclosed |
| US-8501710-B2 | Antiulcer agents; wound healing agents | BIOTEC PHARMACON ASA (NO) | 2013-08-06 | — | — | US | disclosed |
| US-20060194760-A1 | Cosmetic preparations | BIOTEC ASA (NO) | 2006-08-31 | — | — | US | disclosed |
| US-6875754-B1 | Use of water-soluble β-(1,3) glucans as agents for producing therapeutic skin treatment agents | BIOTEC ASA (NO) | 2005-04-05 | — | — | US | disclosed |
| US-6858214-B1 | Use of nanoscalar water-soluble β-(1,3) glucans | BIOTEC ASA (NO) | 2005-02-22 | — | — | US | disclosed |
| US-20050009781-A1 | Methods of skin treatment and use of water-soluble beta-(1,3) glucans as active agents for producing therapeutic skin treatment agents | BIOTEC PHARMACON ASA (NO) | 2005-01-13 | — | — | US | disclosed |
| US-6706696-B1 | MIXTURES OF SPECIFIC GLUCANS AND NUCLEIC ACIDS | BIOTEC ASA (NO) | 2004-03-16 | — | — | US | disclosed |
| US-6500410-B1 | IMPROVING THE PHOTO SENSITIVITY AND SOLUBILITY OF UV LIGHT PROTECTION FACTOR IN SUN PROTECTING AGENTS COMPRISING INCLUDING WATER SOLUBLE BETA-(1,3) GLUCANS WHICH ARE SUBSTANTIALLY FREE FROM BETA-(1,6) LINKAGES | BIOTEC PHARMACON ASA (NO) | 2002-12-31 | — | — | US | disclosed |
| US-6497865-B1 | PREPARATIONS CONTAINING WATER SOLUBLE BETA-(1,3) GLUCANS, SUBSTANTIALLY FREE FROM BETA-(1,6) LINKAGES, AND POLYMERS; DECREASES TENDENCY TO FORMING OF STRESS CRACKS | BIOTEC PHARMACON ASA (NO) | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194760-A1 | Cosmetic preparations | GLA, CHIT1, ALG1 | CNR2 4460/4885CNR1 3749/4885CA12 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.